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Abstract
Background—In high tuberculosis (TB) burden countries a significant proportion of the latent 
TB reservoir is established by the age five. There are critical knowledge gaps in our understanding 
of the age-specific prevalence of TB infection and the influence of HIV exposure on TB infection 
in the first five years of life among HIV-uninfected children in sub-Saharan Africa.
Methods—We measured TB infection with the Quantiferon Gold-in-Tube (QFT) and tuberculin 
skin tests (TST) in 447 children ≤60 months and their 284 HIV-infected and uninfected mothers in 
rural Uganda.
Results—The overall prevalence of TB infection in children ≤60 months by TST was 24% (95% 
CI 19.9-27.9). The prevalence of TST positivity was highest among children in their first year of 
life (36%, 95% CI: 26.0-45.9), and declined with age to 19% at 36-60 months of age, chi-square 
test for trend p=0.014. In contrast, 4% (95% CI: 1.9-5.87%) of children had a positive QFT, and 
there was no trend detected with age, p=0.576. QFT positivity was detected as early as 5 months. 
HIV-exposed uninfected (HEU) children had significantly higher odds of TB infection by QFT 
(OR 21.2, p=0.008, 95% CI: 2.2-204.7) or positive TST or QFT (OR 2.4, p=0.020, 95%CI: 
1.2-5.1) compared to HIV unexposed uninfected (HUU) children, adjusting for age, BCG 
vaccination, and a positive maternal TST or QFT.
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Conclusions—An appreciable prevalence of TB infection was detected in early childhood. HIV-
exposed uninfected children (HEU) have a higher risk for TB infection compared to children born 
to HIV uninfected mothers.
Keywords
Childhood TB infection; Latent TB infection; HIV exposed children
The World Health Organization estimates that a third of the world's population has latent 
tuberculosis (TB) infection (LTBI)1 and a significant portion of this latent TB reservoir is 
established in childhood.2–5 By the age of five years, tuberculin skin test (TST) positivity 
ranges from 12%-20%4–7 in South Africa and 12% in Kampala, Uganda.8 Despite evidence 
of a high prevalence of TB infection by the age five years, data characterizing the age 
specific prevalence in this age group are sparse.
The dual epidemic of HIV and TB is a leading cause of morbidity and mortality among 
children and adults in sub-Saharan Africa, but there are little data on the association between 
TB and perinatal HIV exposure among HIV-uninfected children. Despite being born free of 
HIV infection, HIV-exposed uninfected (HEU) children remain at increased risk of 
morbidity and mortality compared to HIV-unexposed uninfected children (HUU).9–11 This 
relationship is thought to be mediated by (1) direct immunologic effects associated with 
perinatal HIV exposure12 and (2) indirect factors, including poverty and increased exposure 
to maternal infections.9 Studies in South Africa and Kenya suggest a high prevalence of 
household TB exposure,13,14 active TB disease,15 and TB infection16 in HIV-exposed 
infants. To our knowledge there are no studies that examine this association beyond 1 year of 
age or compare the risk of TB infection to a concurrent sample of HUU children.
To address these knowledge gaps in the epidemiology of TB in early childhood, we assessed 
the age-specific prevalence of TB infection in children under age five years and the 
association between HIV exposure and TB. We used both TST and Quantiferon Gold-in-
Tube Assay (QFT-IT) (Cellestis, Carnegie, Australia) to measure latent TB in children, due 
to concerns about false positive TST in children who have received bacille Calmette-Guérin 
vaccination (BCG).
METHODS
Study Design
We conducted a cross-sectional study of HIV-infected and HIV-uninfected mothers and their 
children ages 0-60 months. Mothers and children were recruited from the PROMOTE 
cohorts in Tororo, Uganda. In brief, the PROMOTE studies were designed to assess HIV and 
malaria outcomes in mothers and their children; the design of the PROMOTE trials 
(NCT00993031, NCT00948896) have been described previously.17,18 Tororo is a rural 
district in Eastern Uganda with an adult TB incidence of 400/100,000 with 60% of incident 
cases occurring in adults with HIV infection.19 Routine BCG vaccination is given at birth, 
and national BCG coverage in Uganda is 94%.20 Children and mothers presenting for 
routine visits to the study clinic were consecutively approached for study enrollment from 
Marquez et al. Page 2
Pediatr Infect Dis J. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
February to August 2013. Enrollment continued until 300 mothers were recruited with the 
aim to recruit 150 HIV-infected and 150 HIV-uninfected mothers. This sample size achieves 
a power at a 0.05 significance (alpha, two-sided) to detect an odds ratio of 2, assuming TST 
positivity of at least 13% in HUU.8 One child per mother was already enrolled in 
PROMOTE, but all mothers’ children age five and under were eligible. Mothers and children 
with a positive symptom screen or TB contact were assessed by study clinicians and referred 
to the local TB clinic for active TB evaluation. Active TB was not an exclusion criterion, as 
our study was not designed to exclude active disease and our primary outcome measure, TB 
infection, could include active and LTBI. One mother and child had a clinical diagnosis of 
active TB. All children participating in the PROMOTE cohorts were HIV-uninfected.
Study Measures
On enrollment all mothers completed a questionnaire on household demographics, history of 
household TB exposures, and a standardized TB symptom screen for adults21 and their 
children.22 Height and weight were measured for all children and malnutrition was defined 
per WHO criteria.23 All mothers and children participating in the PROMOTE trial 
completed HIV testing, and children were defined as HIV-uninfected once they had a 
negative HIV-1 DNA PCR 6 weeks after cessation of breastfeeding.
Quantiferon Gold-In-Tube Assays (Cellestis, Carnegie, Australia)—Blood 
samples were incubated and processed within six hours of collection. Following incubation 
all samples were stored in a −20°C freezer until the assays were run in batch at an on-site 
laboratory according to the manufacturer's instructions.24 The person performing the assay 
was blind to TST results and health-related information.
Tuberculin Skin Tests—To negate any possibility of the TST inducing a false positive 
IGRA response, all TSTs were placed after phlebotomy for the QFT. As recommended by 
the manufacturer, 5 tuberculin units of Aplisol (PPD-S) tuberculin were injected 
intradermally into the volar aspect of the forearm. The largest transverse diameter of 
induration was measured by a trained research assistant using the “ball-point” technique 48 
to 72 hours after TST placement25 At the study onset Tubersol was used for 20 TSTs, but we 
switched to Aplisol tuberculin due to a global Tubersol shortage. Tubersol and Aplisol have 
similar sensitivities and specificities.26
Data and Statistical Analysis
Data were double entered into a Microsoft Access database and statistical analysis was 
performed using STATA software, version 12 (StataCorp, College Station, TX). 
Comparisons between demographics of children born to HIV-infected and HIV-uninfected 
mothers were performed using Pearson chi-square and the Wilcoxon rank sum tests as 
appropriate. Concordance between TST and QFT was assessed with the kappa statistic.27
The primary outcome of the study was TB infection in children. Given lack of a gold 
standard test for TB infection we defined it as (1) Positive TB test: positive TST or QFT or 
(2) Positive QFT. For analyses, unless otherwise specified, a positive TST was defined as 
≥10mm for children and HIV-negative adults. A cut off of ≥5mm was used for HIV-infected 
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mothers and severely malnourished children (weight for height Z-score <-3). We also 
present data using an alternative TST cut-off of ≥15mm, and age-specific cut-offs proposed 
by Chan et al.28 (positive TST defined as ≥21mm from 0-1 years, ≥18mm from age 2-3 
years, and ≥13mm from 4-5 years). A positive QFT was defined per the manufacturer's 
guidelines.24 We used logistic regression models with robust standard errors to account for 
clustering by family to obtain point estimates and 95% confidence intervals (CI).
To assess the relationship between HIV exposure and TB infection, we restricted our 
analysis to the 281 children who had a documented HIV-1 DNA PCR after cessation of 
breastfeeding, which was done as part of the PROMOTE trials. The primary exposure 
variable of interest was perinatal HIV exposure. Bivariate logistic regression was used to 
generate odds ratios for covariates of interest and for the primary outcome. Multivariate 
models were then constructed to assess relationships between the primary outcome, perinatal 
HIV exposure and covariates associated with TB infection. Covariates were included in the 
model if the p-value was less than 0.10. Age, presence of a BCG scar, and maternal TB 
infection (QFT and/or TST positivity) were included a priori in multivariate logistic 
regression models, given previously established associations between these variables and TB 
infection.29,30 Reported household TB exposure was not included in the model given as it is 
on the causal pathway between HIV exposure and TB infection. Interactions between HIV 
exposure and age were explored but were not significant. Socioeconomic status was assessed 
by performing principal component analysis of questions regarding household possessions, 
as previously described.31
ETHICS
This study was approved by the Makerere University School of Medicine Research and 
Ethics Committee, Uganda National Council for Science and Technology, and the University 
of California, San Francisco Committee on Human Research. Written informed consent for 
the study was obtained from mothers.
RESULTS
Participant Characteristics
We enrolled 151 HIV-uninfected and 149 HIV-infected women and their 476 children ≤60 
months. See Figure, Supplementary Digital Content 1 for the study flow diagram. There 
were no significant differences in age, maternal HIV status, poverty, or TB exposure 
between those who completed all study measurements and those who did not.
Study characteristics are presented in Table, Supplementary Digital Content 2. Children 
ranged in age from 1.7 to 59.7 months, with a median age of 34.3 months (IQR 12.2-36.5). 
Children born to HIV-infected mothers were younger, had a higher proportion of wasting, 
and lived in households that had a higher proportion of adults with a self-reported history 
TB. 71% of the HIV-infected women reported taking antiretroviral therapy (ART). Gender, 
household crowding, and proportion of children with a BCG vaccination scar were similar 
between groups.
Marquez et al. Page 4
Pediatr Infect Dis J. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Maternal TB infection rates differed by test and by HIV status. A higher proportion of HIV-
infected mothers compared to HIV-uninfected mothers had a positive TST or QFT (59% vs. 
42%, p<0.001), but there was no difference in positive QFTs (40% vs. 40%, p=0.96). 
Concordance between QFT and TST among mothers was moderate, kappa=0.512. 
Agreement between TST and QFT was 76.4%, and a higher proportion of HIV-infected 
women compared to HIV-uninfected women had a positive QFT with a negative TST, 14% 
vs. 9% p<0.001.
Age-Specific Prevalence of TB Infection in Children
The overall proportion of positive TSTs was 23.9% (95% CI 19.9-27.9). A positive TST 
(≥10mm) was detected as early as 2.6 months. When stratified by age group, the highest 
prevalence of TST positivity was among children in their first year of life (36%, 95% CI: 
26.0-45.9) and TST positivity declined with age, chi-square test for trend: p=0.014 (Figure 
1A). Applying alternative criteria for TST positivity resulted in a lower proportion of 
positive TSTs: 8.9% (95% CI: 6.2-11.6) using ≥15mm and 3.0% (95% CI: 1.4-4.6) using the 
Chan et al.28 age-specific cut-offs (Figure 2).
A positive QFT was detected as early as 5.0 months. The overall prevalence of positive 
QFTs was 3.9% (95% CI: 1.9-5.8); 7.2% of children had an indeterminate QFT (97% were 
failed negative controls and 3% were failed positive controls). We did not detect a trend in 
QFT-positivity by age-category (p=0.634) (Figure 1B).
Concordance of TST and QFT positivity in children was poor, κ=0.046, 2% of children had 
a TST+/QFT+ result, 72% had a TST−/QFT− results, 24% had a TST +/QFT−, and 2% had 
a TST−/QFT+ result. Comparing induration size to QFT positivity, 43% of positive QFTs 
occurred among children whose TST induration ≥ 15mm, and the remaining children with a 
positive QFT had a TST induration of 0mm. Concordance was poor when a 15mm cut off 
was used for TST positivity (κ=0.209), 2% of children had a TST+/QFT+ result, 89% had a 
TST−/QFT− results, 8% had a TST+/QFT−, and 2% had a TST−/QFT+.
Association between HIV exposure and TB Infection
Children born to HIV-infected mothers had a higher prevalence of positive QFTs compared 
to those who were born to HIV-uninfected mothers (6.4% vs. 1.5%, p= 0.01) (Figure 1B). 
We saw a trend towards a higher proportion of positive TSTs in children born to HIV-
infected mothers compared to those born to HIV-uninfected mothers (27.2% vs. 20.6%, 
p=0.11) (Figure 1C).
Bivariate and multivariate analyses are shown in Table 1. In multivariate models we found 
HEU children had 21-fold higher odds of a positive QFT compared to HUU (OR 21.2, 
p=0.008, 95% CI:2.2-204.7), adjusting for age and maternal TB infection (Table 1A). When 
TB infection is defined as any positive TB test (TST≥10mm or positive QFT), HEU have a 
2-fold increased odds of TB infection (OR 2.4, p=0.020, 95%CI: 1.2-5.1) compared to 
HUU, adjusting for age, maternal TB infection, and BCG scar (Table 1B). Maternal TB 
infection is an independent risk factor for childhood TB infection as measured by a positive 
TB test or QFT in adjusted models, and presence of BCG scar is only an independent risk 
factor for a positive TB test. The increased risk of TB infection among HEU compared to 
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HUU children persists when TB infection is defined as a positive TST per the age-specific 
cut-offs proposed by Chan et al.28 (OR: 12.3, 95% CI: 2.1-72.1), adjusting for age, maternal 
TB infection, and BCG vaccination.
DISCUSSION
In this cross-sectional study of Ugandan children, we found an appreciable prevalence of 
positive TSTs and QFTs in the first five years of life, and we detected QFT positivity as 
early as 5 months. Our data support prior findings of a high prevalence of TB infection 
among HIV-exposed infants in sub-Saharan Africa.9,14,16 Additionally, these data suggest 
that an increased risk of TB infection among HIV-exposed children exists for the first five 
years of life, independent of BCG vaccination and maternal TB infection.
We found a large difference between TST and QFT positivity. We hypothesize that much of 
this difference can be attributed to false positive TSTs from BCG vaccination, the effect of 
which wanes with age. Our age-specific data on TST positivity were consistent with age-
specific trends from a national TST survey in Taiwan.28 In this survey Chan et al. found the 
highest prevalence of TST positivity in the first year of life (approximately 60%) with a 
nadir at 6-7 years of age, which they attributed to a waning BCG effect. In Gambia, 22% of 
BCG vaccinated infants had a positive TST at 4.5 months compared to 1% of unvaccinated 
infants, suggesting a high proportion of TST positivity in the first year of life is attributable 
to BCG vaccination.32 A non-linear trend of TB infection in children under age five and 
survivorship bias inherent in prevalence surveys are alternative explanations of the negative 
association of TST positivity and age.
Interferon Gamma Release Assays (IGRA) do not cross-react to BCG vaccination, and thus 
have been proposed as a more specific means to measure TB infection in prevalence surveys. 
To our knowledge the only two studies that examine the prevalence of TB infection with an 
IGRA among children five and under from the general population in East Africa are a 
retrospective study in Kenya, which found 11% of HIV-exposed to have a positive T-
SPOT.TB16 and a prospective study of five year olds in Entebbe, Uganda, in which 10% of 
children were found to have a positive T-SPOT.TB.33 These estimates are higher than our 
estimate for QFT positivity among our HEU children, and we suspect this is due to 
differences in the sample: the Entebbe cohort was older and urban and the Kenyan cohort 
included HIV-infected children, different test characteristics of the T-SPOT.TB compared to 
the QFT,34 and the majority of mothers were not receiving antiretroviral therapy (ART).
The lower prevalence of QFT positivity compared to TST positivity in our study could also 
be partially attributable to false negative QFTs. False-negative IGRAs could be due to age-
inappropriate interferon gamma cut-offs, as young children are thought to produce lower 
amounts of IFN-ϒ in response to antigens.35,36 Additionally, younger children may 
preferentially exhibit a T helper-2 response to TB infection which is detected with the TST 
but not the IGRA.37 Longitudinal studies are necessary to determine the most accurate test 
for detecting TB infection in this early age group.
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Revised age-specific cut-offs for diagnosing LTBI with TSTs may better account for the 
BCG effect in early childhood. IGRAs may be a more specific method for detecting TB 
infection, but they are more expensive, require more laboratory infrastructure, and may have 
a higher probability of false negatives compared to TST, thereby making it a difficult test to 
implement on a wider-scale in resource limited settings. In this study, when using TST cut-
offs ≥15 mm or age-specific cut-offs such as those proposed by Chan et al., we found a TST 
prevalence closer to that found by the QFT. Applying optimized age-specific cut-offs in 
high-TB burden settings in East Africa may improve estimates of the prevalence of 
childhood TB infection in future TST surveys.
This study identified HEU children as a high-risk population for TB infection, with higher 
odds of QFT and TST test positivity compared to HUU children. Increased TB exposure in 
the home may underlie this association, as a higher number of household TB contacts were 
reported in the households of HIV-infected mothers in our study and in other studies from 
sub-Saharan Africa. HEU, compared to HUU, may have a higher risk of acquiring TB 
infection from their mothers. HIV-infected mothers are at a high risk of TB reactivation or 
developing active disease if infected, especially in the peripartum period.38,39 Studies on 
HIV-infected women in PMTCT cohorts in India30 and Kenya29 show a high rate of TB 
disease in the post-partum period, 5 and 3.5 per 100 person years, respectively. In these 
cohorts TST and IGRA were both predictive of maternal TB infection as well as infant death 
or childhood TB disease. Our study complements these findings, as we found a positive 
maternal TST or IGRA independently predicted TB infection in children.
Immunologic differences between HEU and HUU may also contribute to the relationship 
between HIV exposure and childhood TB infection. In utero exposure to maternal infections, 
including HIV, is hypothesized to prime the developing immune system leading to impaired 
T and B cell immune responses.40–43 Several studies have found impaired BCG 
immunogenicity and interferon gamma response to PPD among HEU infants.43–46 Jones et 
al. found a relationship between impaired T-lymphocyte responses to BCG and both HIV 
exposure and maternal TB sensitization (positive IGRA) among South African infants at 
birth, but this relationship was no longer detected at 16 weeks of life. Additional data are 
needed to assess the duration of immunologic differences between HEU and HUU and the 
correlation between clinical outcomes and immunologic differences.
Our study has important strengths and limitations. We were not able to determine the 
accuracy of each test in this population, as there is no gold standard for LTBI. However, by 
using both tests we were able to provide an upper and lower estimate of TB infection in this 
sample, as well as highlight future research directions for estimating TB infection in this 
vulnerable age group. While we were able to highlight age-specific trends in TST positivity 
we were not powered enough to detect age-specific differences in QFT prevalence. Due to 
the cross-sectional nature of this study we were not able to account for survivorship bias and 
age-cohort effects that could have affected age-specific trends in TB infection. Advanced 
maternal immunosuppression has been associated with a higher risk of morbidity and 
mortality among HEU,47,12,29 thus it is possible that our study underestimates the risk of TB 
infection among HEU children given 70% of women in our study are on ART. Lastly, 
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generalizability may be limited as the sample was recruited from women and children 
participating in a clinical trial on malaria and HIV.
Strategies are needed to address this appreciable prevalence of childhood TB infection and 
to decrease the size of the latent TB reservoir. Antenatal and PMTCT clinics are ideal for 
locations targeted TB-control interventions,39 as these are common settings where HIV-
infected women interface with the health care system. Scaling-up proven interventions such 
as isoniazid preventive therapy (IPT) and TB screening among HIV-infected women are 
likely to benefit both mother and child. Contact tracing and IPT in children is feasible and 
high yield, but rarely implemented in East Africa.48,49 Overall, these data highlight the 
importance of targeted TB prevention efforts in early childhood, especially among young 
children born to HIV-infected mothers.
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Figure 1. Proportion of positive Tuberculin Skin Tests (TST) and Quantiferon Gold In Tube 
Tests (QFT), stratified by age and mother's HIV status
A. Proportion of positive TST and QFTs among children ≤60 months, stratified by age-
category. There is a negative trend in TST positivity with increasing age, chi-square test for 
trend p=0.014. The trend of QFT positivity and age was not statistically significant, chi-
square test for trend p=0.576. B. Proportion of positive QFTs, stratified by a HIV-status of 
mother. Children had a higher proportion of positive QFTs for all age-categories, though this 
was not statistically significant for any age-categories. C. Proportion of positive TSTs, 
stratified by age and mother's HIV-status. Children born to HIV-infected mothers had a 
higher prevalence of TST positivity in the 24-35 month age-category (p=0.013) and the 
36-60 month age group (p=0.001) compared to the children born to HIV-uninfected mothers 
in the same age-group. A positive TST is defined as induration ≥10mm.
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Figure 2. Quantiferon Gold-In-Tube (QFT) and Tuberculin Skin (TST) positivity among children 
≤60 months, using different definitions for TST cut offs for positivity
*age-specific cut-off proposed by Chan et al.28 (positive TST defined as ≥21mm from 0-1 
years, ≥18mm from age 2-3 years, and ≥13mm from 4-5 years).
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